In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing

J Thorac Oncol. 2019 Dec;14(12):e279-e280. doi: 10.1016/j.jtho.2019.10.010.

Authors

Sehhoon Park¹, Se-Hoon Lee¹, Keunchil Park²

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: kpark@skku.edu.

PMID: 31757381
DOI: 10.1016/j.jtho.2019.10.010

No abstract available

Publication types

Letter
Comment

MeSH terms

Cisplatin
DNA Damage
Exome
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms / genetics*
Mutation
Platinum
Small Cell Lung Carcinoma*

Substances

Platinum
Cisplatin